Indaptus Therapeutics is trading 6% down at $2.65 today, giving back a portion of its recent gains following a sharp move higher on July 15, 2026.
- The stock appears to be in a consolidation phase as there are no fresh company-specific headlines or SEC filings released today.
- Shares previously saw upward momentum driven by news regarding Nasdaq bid-price compliance alongside clinical and strategic updates shared earlier this year.